Dog Vaccines Market Growth, Size, Trends Analysis - By Vaccine Type, By Disease Type, By Route of Administration, By Duration of Immunity, By Component, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Dog Vaccines Market Introduction and Overview

According to SPER market research, 'Global Dog Vaccines Market Size- By Vaccine Type, By Disease Type, By Route of Administration, By Duration of Immunity, By Component, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Dog Vaccines Market is predicted to reach 3.79 billion by 2034 with a CAGR of 6.68%.

Vaccines help prepare a dog's immune system to defend against any invasion of pathogenic organisms. Antigens in vaccines mimic disease-causing organisms in the dog's immune system without actually causing illness. The market for dog vaccines is expanding quickly, which is explained by the fact that puppy and dog vaccines work to gradually boost immunity by detecting the presence of antigens. In this way, if a dog develops a predisposition to the disease, its immune system will recognize it and be set up to fight it or, at most, lessen its effects.

The market's expansion is hampered by factors including strict regulations, the high expense of developing vaccines, and the requirement for cold chain logistics to guarantee vaccine effectiveness. Further impeding expansion is the occasional immunization hesitation among pet owners brought on by false information or worries about unpleasant reactions.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Vaccine Type, By Disease Type, By Route of Administration, By Duration of Immunity, By Component, By Distribution Channel

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered Boehringer Ingelheim International GmbH, Zoetis Services LLC, Merck & Co., Inc, Elanco, Hester Biosciences Limited, Virbac, Bioveta a.s, Brilliant Bio Pharma, Heska Corporation, Zendal Group.

Dog Vaccines Market Segmentation:

By Vaccine Type: Based on the Vaccine Type, Global Dog Vaccines Market is segmented as; Modified/ Attenuated Live, Inactivated, Other Vaccines.

By Disease Type: Based on the Disease Type, Global Dog Vaccines Market is segmented as; Canine Distemper, Canine Infectious Respiratory Disease Complex, Canine Parvovirosis/ Parvovirus Disease, Canine Leptospirosis, Canine Lyme Disease, Infectious Canine Hepatitis, Canine Rabies, Other Diseases.

By Route of Administration: Based on the Route of Administration, Global Dog Vaccines Market is segmented as; Injectables, Intranasal, Oral.

By Duration of Immunity: Based on the Duration of Immunity, Global Dog Vaccines Market is segmented as; 1 Year, 3 Year, Others.

By Component: Based on the Component, Global Dog Vaccines Market is segmented as; Combined Vaccines, Mono Vaccines.

Product Code: HLCA2507

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Dog Vaccines Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Dog Vaccines Market

7. Global Dog Vaccines Market, By Vaccine Type (USD Million) 2021-2034

7.1. Modified/ Attenuated Live
7.2. Inactivated (Killed)
7.3. Other Vaccines

8. Global Dog Vaccines Market, By Disease Type (USD Million) 2021-2034

8.1. Canine Distemper
8.2. Canine Infectious Respiratory Disease Complex (CIRDC)
8.3. Canine Parvovirosis/ Parvovirus Disease
8.4. Canine Leptospirosis
8.5. Canine Lyme Disease
8.6. Infectious Canine Hepatitis
8.7. Canine Rabies
8.8. Other Diseases

9. Global Dog Vaccines Market, By Route of Administration (USD Million) 2021-2034

9.1. Injectables
9.2. Intranasal
9.3. Oral

10. Global Dog Vaccines Market, By Duration of Immunity (USD Million) 2021-2034

10.1. 1 Year
10.2. 3 Year
10.3. Others

11. Global Dog Vaccines Market, By Component (USD Million) 2021-2034

11.1. Combined Vaccines
11.2. Mono Vaccines

12. Global Dog Vaccines Market, By Distribution Channel (USD Million) 2021-2034

12.1. Retail
12.2. E-Commerce
12.3. Hospital/Clinic Pharmacies

13. Global Dog Vaccines Market (USD Million) 2021-2034

13.1. Global Dog Vaccines Market Size and Market Share

14. Global Dog Vaccines Market, By Region (USD Million) 2021-2034

14.1. Asia-Pacific
- 14.1.1. Australia
- 14.1.2. China
- 14.1.3. India
- 14.1.4. Japan
- 14.1.5. South Korea
- 14.1.6. Rest of Asia-Pacific
14.2. Europe
- 14.2.1. France
- 14.2.2. Germany
- 14.2.3. Italy
- 14.2.4. Spain
- 14.2.5. United Kingdom
- 14.2.6. Rest of Europe
14.3. Middle East and Africa
- 14.3.1. Kingdom of Saudi Arabia
- 14.3.2. United Arab Emirates
- 14.3.3. Qatar
- 14.3.4. South Africa
- 14.3.5. Egypt
- 14.3.6. Morocco
- 14.3.7. Nigeria
- 14.3.8. Rest of Middle-East and Africa
14.4. North America
- 14.4.1. Canada
- 14.4.2. Mexico
- 14.4.3. United States
14.5. Latin America
- 14.5.1. Argentina
- 14.5.2. Brazil
- 14.5.3. Rest of Latin America

15. Company Profile

15.1. Zoetis
- 15.1.1. Company details
- 15.1.2. Financial outlook
- 15.1.3. Product summary
- 15.1.4. Recent developments
15.2. Boehringer Ingelheim International GmbH
- 15.2.1. Company details
- 15.2.2. Financial outlook
- 15.2.3. Product summary
- 15.2.4. Recent developments
15.3. Merck & Co., Inc
- 15.3.1. Company details
- 15.3.2. Financial outlook
- 15.3.3. Product summary
- 15.3.4. Recent developments
15.4. Elanco
- 15.4.1. Company details
- 15.4.2. Financial outlook
- 15.4.3. Product summary
- 15.4.4. Recent developments
15.5. Virbac
- 15.5.1. Company details
- 15.5.2. Financial outlook
- 15.5.3. Product summary
- 15.5.4. Recent developments
15.6. Bioveta a.s
- 15.6.1. Company details
- 15.6.2. Financial outlook
- 15.6.3. Product summary
- 15.6.4. Recent developments
15.7. Hester Biosciences Limited
- 15.7.1. Company details
- 15.7.2. Financial outlook
- 15.7.3. Product summary
- 15.7.4. Recent developments
15.8. Brilliant Bio Pharma
- 15.8.1. Company details
- 15.8.2. Financial outlook
- 15.8.3. Product summary
- 15.8.4. Recent developments
15.9. Heska Corporation
- 15.9.1. Company details
- 15.9.2. Financial outlook
- 15.9.3. Product summary
- 15.9.4. Recent developments
15.10. Zendal Group
- 15.10.1. Company details
- 15.10.2. Financial outlook
- 15.10.3. Product summary
- 15.10.4. Recent developments
15.11. Others